Company: CERO
Filing Date: 2025-10-23
Form Type: 424B3
Source: 0001213900-25-101651
Chunk: 2

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-10-23
Form: 424B3
Chunk 2
---
 pursuant to Rule 425 under the Securities Act (17 CFR 230.425)                  |
| ☐ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)                 |
| ☐ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ☐ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |

Securities registered pursuant to Section 12(b) of the Act:

| Title of each class                                                                  |     | Trading Symbol(s) |     | Name of each exchange on which 
 registered                     |
| Common Stock, par value $0.0001 per share                                            |     | CERO              |     | Nasdaq Capital Market          |
| Warrants, each warrant exercisable for one two-thousandth of a share of Common Stock |     | CEROW             |     | Nasdaq Capital Market          |

Indicate by check mark whether the registrant is an emerging growth
company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934.

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant
has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant
to Section 13(a) of the Exchange Act. ☐

Item 7.01 Regulation FD Disclosure.

On September 22, 2025, CERo Therapeutics Holdings, Inc., a Delaware
corporation (the “Company”), updated its corporate presentation, which it plans to use in meetings with investors,
analysts and others. The presentation can be found on the Company’s website, www.cero.bio. The information set forth on the Company’s website is not included or incorporated by reference herein. A copy of this corporate presentation is furnished hereto as Exhibit 99.1.

The information in this Item 7.01 and Exhibit 99.1 attached hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “ Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing